NIH demands diverse clinical trials—drugmakers face new compliance costs
S. 3564 — NIH Clinical Trial Integrity Act · Filed by Andy Kim (D-NJ) · 1 cosponsor · Introduced Dec 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires NIH-funded clinical trials to set clear, measurable goals for recruiting and retaining participants from diverse racial, ethnic, age, and sex groups that match the disease prevalence or general U.S. population. It mandates annual reporting of participant demographics, researcher training on diversity, and a study on removing cost barriers to trial participation—including updated rules on reimbursing participants for expenses and time. It also funds a $10 million national awareness campaign and grants to community organizations to increase diverse participation in clinical trials.
Why we flagged it
The bill's core mechanism is a regulatory requirement on NIH-funded trials to achieve demographic representation and reduce participation barriers. It is a public-health transparency and equity measure, not a tax provision, appropriation, or commemorative act.
What the text implies
- Pharmaceutical and biotech companies conducting NIH-funded trials will face increased administrative burden and cost to track, report, and recruit diverse cohorts; this may slow trial timelines and increase R&D expenses, potentially affecting drug development speed and pricing.
- The requirement to analyze safety/efficacy separately by demographic group may reveal previously unknown disparities in drug response, leading to label changes, restricted indications, or post-market surveillance obligations that affect market access.
- The $10M grant program and national awareness campaign may shift trial recruitment patterns, reducing reliance on traditional (often less diverse) recruitment channels and increasing competition for participants among sponsors.
- Privacy protections are stated but aggregated demographic reporting to NIH creates a new federal database of trial participant characteristics; long-term use and re-identification risk are not addressed.
- The 2-year study on cost barriers and anti-kickback safe harbors may lead to future regulatory changes that expand permissible participant compensation, potentially increasing trial costs or creating new compliance risks.
Who it affects
Ordinary citizens—particularly those from historically underrepresented racial, ethnic, age, and sex groups—gain access to clinical trials and benefit from research that reflects their health needs. Removing cost barriers and improving recruitment strategies makes trials more accessible. The transparency requirements and diversity goals help ensure that drug and device safety/efficacy data are representative, protecting all patients from treatments tested only on narrow populations.
Who stands to gain
- Community-based organizations and nonprofits (grant recipients)
- Faith-based organizations (grant recipients)
- Institutions of higher education (grant recipients)
- Community pharmacies (grant recipients)
- Pharmaceutical and biotech companies (indirectly, via improved trial data and market access)
Named in the bill
National Institutes of Health (NIH), Secretary of Health and Human Services (HHS), Food and Drug Administration (FDA), Health Resources and Services Administration (HRSA), Office on Minority Health (OMH), Centers for Disease Control and Prevention (CDC), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Federal Anti-Kickback Statute — and 1 more
Where it stands
1 cosponsor: 1 Republicans.
- Dec 18, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Dec 18, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $40,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Andy Kim, the sponsor, reported $74,900 in PAC receipts in the 2026 cycle.
- Patient Access Network Foundation — $40,000 on 1 filing
Lobbying Disclosure Act filings through Jan 6, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Dec 2025. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jan 6, 2026 · page rendered 2026-10-20.
“NIH demands diverse clinical trials—drugmakers face new compliance costs” QuorumCivic. https://share.quorumcivic.app/bill/119/s3564 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.